{{Drugbox
| Watchedfields = changed
| verifiedrevid = 444454940
| IUPAC_name = 5-[(Methylthio)methyl]-3-{[(1''E'')-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
| image = Nifuratel.svg
| width = 275

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|nifuratel}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4936-47-4
| ATC_prefix = G01
| ATC_suffix = AX05
| PubChem = 6433427
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U60U6P08SP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01050
| ChemSpiderID      = 4938579

<!--Chemical data-->
| C=10 | H=11 | N=3 | O=5 | S=1 
| molecular_weight = 285.28 g/mol
| smiles = CSCC1CN(C(=O)O1)/N=C/C2=CC=C(O2)[N+](=O)[O-]
| StdInChI = 1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
| StdInChIKey = SRQKTCXJCCHINN-NYYWCZLTSA-N

}}

'''Nifuratel''' (brand name '''Macmiror''', or — in combination with [[nystatin]], — '''Macmiror Complex''') is a drug used in [[gynecology]]. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.

Nifuratel appears to have a broad antibacterial spectrum of action and is effective against ''[[Chlamydia trachomatis]]'' and ''Mycoplasma spp.'' as well as fungal infections from ''Candida spp.''<ref>Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey</ref>

Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example, it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is ''Trichomonas vaginalis'' or ''Candida'' strains such as ''Candida albicans''.

Side effects appear to be minimal or non-existent and it has a safe toxicological profile.<ref>Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review.  Werner Mendling,  Federico Mailland
Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.</ref>

==References==
{{Reflist}}

{{Gynecological anti-infectives and antiseptics}}

[[Category:Thioethers]]
[[Category:Oxazolidinones]]
[[Category:Nitrofurans]]